Cefepime dosing in the morbidly obese patient population. - Wikidata - wikimedia - TriplyDB

Cefepime dosing in the morbidly obese patient population.

Cefepime dosing in the morbidly obese patient population.

http://www.wikidata.org/entity/Q44189639

about

Antibiotic therapy of pneumonia in the obese patient: dosing and delivery Obesity Is Not Associated with Antimicrobial Treatment Failure for Intra-Abdominal Infection.The Daniel K. Inouye College of Pharmacy Scripts: Obesity: The Drug Dose Debate.Broad-spectrum β-lactams in obese non-critically ill patients.Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies Case-control study of drug monitoring of β-lactams in obese critically ill patients.Antiobesity Effects of the Ethanol Extract of Laminaria japonica Areshoung in High-Fat-Diet-Induced Obese Rat.Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms Antibiotic dosing in obesity: the search for optimum dosing strategies.Interaction of obesity and infections.Therapeutic management of peritonitis: a comprehensive guide for intensivists.Anti-obesity and cardioprotective effects of cinnamic acid in high fat diet- induced obese rats.Monoterpene phenolic compound thymol prevents high fat diet induced obesity in murine model.

P2860

Q29248400-EEC46B3B-28ED-4D34-969B-1C34D7358388 Q30277073-FBADCEA0-FF52-473B-A86C-D4AFA250BB1E Q33763123-C926ED3F-D2F4-4A24-9C25-BDC04DED31B4 Q33839225-9D319610-864C-4324-9713-9AD21D7BDAC2 Q35960873-739AF052-2A76-437A-B9FF-B63F6DEF1CA1 Q36558332-2A20DF23-6F29-4A27-86B8-11CAFC39C1BA Q36566156-F3C911B9-668A-4B28-B127-322ED78C90F6 Q36730158-A84AF530-FFE1-4077-AB82-66FF05E2F250 Q38397264-0F3FDEED-63E9-4C40-BE76-4F266CD99002 Q38583848-EC63FC63-7ADE-4A07-9231-E0BFC1DF14B3 Q40752468-3FD745CA-D2FF-4FE2-8D20-2419F45640FB Q41570942-8568DA5E-20EC-4B24-A39C-EABCCBE19E03 Q44734696-5B1DE9EE-7BC5-4CCF-BFD9-C70B9FB9DBA7

P2860

Cefepime dosing in the morbidly obese patient population.

http://www.wikidata.org/entity/Q44189639

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Cefepime dosing in the morbidly obese patient population.

@en

Cefepime dosing in the morbidly obese patient population.

@nl

type

label

Cefepime dosing in the morbidly obese patient population.

@en

Cefepime dosing in the morbidly obese patient population.

@nl

prefLabel

Cefepime dosing in the morbidly obese patient population.

@en

Cefepime dosing in the morbidly obese patient population.

@nl

P1433

Q44189639-77A9228B-FA40-4667-8410-C3201A066B1B

P1476

Q44189639-AC6EB129-B1A7-47E6-8528-F9C158A73C33

P2093

Q44189639-12512F46-9773-4C27-809E-59FC847BCA07

Q44189639-4E4101F6-5AA7-4A04-85F2-8FB8D3C94DB2

Q44189639-55C88871-E70D-45D8-B41F-EA420575075A

Q44189639-6085F70D-86EF-4BA5-9D98-90F1002CFFF4

Q44189639-A158C99E-91A5-46BE-8886-B0B01A777D39

Q44189639-A3B0E24E-333A-4D74-9CC2-577A2ACF3AA9

Q44189639-E8E38A84-0D90-47F0-899E-C80D474D98F3

Q44189639-EE4B7BB2-43D5-47BB-B10A-98C4BF7585C2

P2860

Q44189639-069F4978-69E0-4CD6-A533-7E74A7C1C9A7

Q44189639-07896423-B57F-430D-B74E-3E27DE1D95DE

Q44189639-09E312F5-DB7F-441D-967F-1D9D050F38AC

Q44189639-0F45F1AB-9F98-4937-B6A0-F0ACD9C4391A

Q44189639-19BBC215-C546-455A-8E64-B63298A79EE6

Q44189639-2BADEAF2-3F61-483A-B88B-C8DD3A900662

Q44189639-3A70432F-7CAC-4C10-829B-D82739A0875C

Q44189639-4545DB3F-9BC6-41B0-8B6B-7ED57B4B73CF

Q44189639-483469D7-9767-4BE4-A07C-7694B945F166

Q44189639-65937911-33B6-4E73-BB7C-F8437195C4ED

P2888

Q44189639-9A200631-F56D-46BB-AE92-0D532124D3A7

P304

Q44189639-D313F783-057E-4BF8-88C0-AEDE62255E17

P31

Q44189639-D293A7A0-4B03-411C-800B-CF261B91380B

P356

Q44189639-498AA50A-E0B8-41D8-AAE4-7B4D372634D8

P433

Q44189639-7DE73134-835E-418B-82A6-5DD0261BCDF6

P478

Q44189639-E4FA154F-977A-4F20-84EC-28674F7E6CD1

P50

Q44189639-FF89B135-BB89-4622-B2DB-8F3F472009AA

P577

Q44189639-10671086-3C93-479D-BCCF-7DB825ECF296

P698

Q44189639-4D4D653A-3B75-4BA4-9DC5-772C2EAE58B5

P921

Q44189639-91D598A2-BC32-45EF-A701-7CE797D621D1

Q44189639-B661931F-8F70-4D09-B669-E84A7C95DD38

P356

S11695-011-0586-8

P1433

Obesity Surgery

P1476

Cefepime dosing in the morbidly obese patient population

@en

P2093

Alfons Pomp

http://www.w3.org/2001/XMLSchema#string

Barrie S Rich

http://www.w3.org/2001/XMLSchema#string

Cheguevara I Afaneh

http://www.w3.org/2001/XMLSchema#string

David P Nicolau

http://www.w3.org/2001/XMLSchema#string

Gregory F Dakin

http://www.w3.org/2001/XMLSchema#string

Harma Turbendian

http://www.w3.org/2001/XMLSchema#string

Philip S Barie

http://www.w3.org/2001/XMLSchema#string

Rebecca Keel

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of cefepime: a systematic review and meta-analysis

Critical care of the bariatric patient.

Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.

Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.

Preventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens.

Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults

Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers.

Surgical site infections.

Pharmacodynamics of antimicrobials: treatment optimisation.

Postoperative complications in obese and nonobese patients.

P2888

s11695-011-0586-8

P304

465-471

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11695-011-0586-8

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22249886

http://www.w3.org/2001/XMLSchema#string

P921